164 related articles for article (PubMed ID: 33275876)
21. DNA binding domain-independent pathways are involved in EWS/FLI1-mediated oncogenesis.
Welford SM; Hebert SP; Deneen B; Arvand A; Denny CT
J Biol Chem; 2001 Nov; 276(45):41977-84. PubMed ID: 11553628
[TBL] [Abstract][Full Text] [Related]
22. Dimerization and DNA recognition rules of mithramycin and its analogues.
Weidenbach S; Hou C; Chen JM; Tsodikov OV; Rohr J
J Inorg Biochem; 2016 Mar; 156():40-7. PubMed ID: 26760230
[TBL] [Abstract][Full Text] [Related]
23. Molecular dynamics studies on the DNA-binding process of ERG.
Beuerle MG; Dufton NP; Randi AM; Gould IR
Mol Biosyst; 2016 Nov; 12(12):3600-3610. PubMed ID: 27714012
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of c-src transcription by mithramycin: structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target.
Remsing LL; Bahadori HR; Carbone GM; McGuffie EM; Catapano CV; Rohr J
Biochemistry; 2003 Jul; 42(27):8313-24. PubMed ID: 12846580
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of ERG and FLI1 expression in endothelial cells triggers endothelial-to-mesenchymal transition.
Nagai N; Ohguchi H; Nakaki R; Matsumura Y; Kanki Y; Sakai J; Aburatani H; Minami T
PLoS Genet; 2018 Nov; 14(11):e1007826. PubMed ID: 30500808
[TBL] [Abstract][Full Text] [Related]
26. ERG and FLI1 protein expression in epithelioid sarcoma.
Stockman DL; Hornick JL; Deavers MT; Lev DC; Lazar AJ; Wang WL
Mod Pathol; 2014 Apr; 27(4):496-501. PubMed ID: 24072183
[TBL] [Abstract][Full Text] [Related]
27. FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer.
Paulo P; Barros-Silva JD; Ribeiro FR; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
Genes Chromosomes Cancer; 2012 Mar; 51(3):240-9. PubMed ID: 22081504
[TBL] [Abstract][Full Text] [Related]
28. Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer.
Malek A; Núñez LE; Magistri M; Brambilla L; Jovic S; Carbone GM; Morís F; Catapano CV
PLoS One; 2012; 7(4):e35130. PubMed ID: 22545098
[TBL] [Abstract][Full Text] [Related]
29. CDK9 Blockade Exploits Context-dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing Sarcoma.
Flores G; Everett JH; Boguslawski EA; Oswald BM; Madaj ZB; Beddows I; Dikalov S; Adams M; Klumpp-Thomas CA; Kitchen-Goosen SM; Martin SE; Caplen NJ; Helman LJ; Grohar PJ
Mol Cancer Ther; 2020 May; 19(5):1183-1196. PubMed ID: 32127464
[TBL] [Abstract][Full Text] [Related]
30. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
[TBL] [Abstract][Full Text] [Related]
31. The Ewing's sarcoma fusion protein, EWS-FLI, binds Runx2 and blocks osteoblast differentiation.
Li X; McGee-Lawrence ME; Decker M; Westendorf JJ
J Cell Biochem; 2010 Nov; 111(4):933-43. PubMed ID: 20665663
[TBL] [Abstract][Full Text] [Related]
32. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.
McKinsey EL; Parrish JK; Irwin AE; Niemeyer BF; Kern HB; Birks DK; Jedlicka P
Oncogene; 2011 Dec; 30(49):4910-20. PubMed ID: 21643012
[TBL] [Abstract][Full Text] [Related]
33. FLI1 and EWS-FLI1 function as ternary complex factors and ELK1 and SAP1a function as ternary and quaternary complex factors on the Egr1 promoter serum response elements.
Watson DK; Robinson L; Hodge DR; Kola I; Papas TS; Seth A
Oncogene; 1997 Jan; 14(2):213-21. PubMed ID: 9010223
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing.
Selvanathan SP; Graham GT; Erkizan HV; Dirksen U; Natarajan TG; Dakic A; Yu S; Liu X; Paulsen MT; Ljungman ME; Wu CH; Lawlor ER; Üren A; Toretsky JA
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1307-16. PubMed ID: 25737553
[TBL] [Abstract][Full Text] [Related]
35. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.
Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK
J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of Vascular Markers (Immunohistochemical Stains) in Soft Tissue Sarcomas.
Naeem N; Mushtaq S; Akhter N; Hussain M; Hassan U
J Coll Physicians Surg Pak; 2018 May; 28(5):352-356. PubMed ID: 29690962
[TBL] [Abstract][Full Text] [Related]
37. Transforming growth factor-beta regulates DNA binding activity of transcription factor Fli1 by p300/CREB-binding protein-associated factor-dependent acetylation.
Asano Y; Czuwara J; Trojanowska M
J Biol Chem; 2007 Nov; 282(48):34672-83. PubMed ID: 17884818
[TBL] [Abstract][Full Text] [Related]
38. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
39. Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.
Sankar S; Theisen ER; Bearss J; Mulvihill T; Hoffman LM; Sorna V; Beckerle MC; Sharma S; Lessnick SL
Clin Cancer Res; 2014 Sep; 20(17):4584-97. PubMed ID: 24963049
[TBL] [Abstract][Full Text] [Related]
40. Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis.
Showpnil IA; Miller KR; Taslim C; Pishas KI; Lessnick SL; Theisen ER
J Vis Exp; 2020 Jun; (160):. PubMed ID: 32658189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
